BlackRock discloses 5.7% stake in VOR Biopharma
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock, Inc. reported beneficial ownership of common stock of VOR BIOPHARMA INC on a Schedule 13G. BlackRock and certain of its business units collectively beneficially own 3,099,259 shares of VOR Biopharma common stock, representing 5.7% of the outstanding class.
BlackRock has sole voting power over 3,057,613 shares and sole dispositive power over 3,099,259 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends or sale proceeds, but no single client holds more than five percent of the company’s outstanding common shares.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
Schedule 13G regulatory
parent holding company regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in VOR BIOPHARMA INC (VOR) does BlackRock report on this Schedule 13G?
How much voting power does BlackRock hold in VOR BIOPHARMA INC (VOR)?
Who ultimately benefits economically from BlackRock’s VOR BIOPHARMA INC (VOR) holdings?
Why is BlackRock filing a Schedule 13G for VOR BIOPHARMA INC (VOR)?
Which BlackRock entities are included in the VOR BIOPHARMA INC (VOR) Schedule 13G?
AI-generated analysis. How Rhea-AI works. Not financial advice.